Fabry Disease | Androgenetic Alopecia in Fabry Disease
Fabry Disease research study
What is the primary objective of this study?
The purpose of this study is to assess whether patients with the classic form of Fabry disease have significantly less androgenic alopecia (male pattern baldness).
Who is eligible to participate?
Inclusion Criteria: - Male patients with Fabry disease age 20-64 years old. - Healthy male controls age 20-64 years old - GLA gene mutations associated with the classic form of Fabry disease or having alpha-galactosidase A activity that is essentially zero - Patients who freely agree to participate in this study and understand the nature, risks and benefits of this study and give their written informed consent.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Patients with the classic form
Fabry disease and healthy controls
Start Date: December 2010
Completed Date: October 2015
Primary Outcome: No and frontal only androgenetic alopecia
Secondary Outcome: Vertex only and frontal and vertex androgenetic alopecia.
Study sponsors, principal investigator, and references
Principal Investigator: Raphael Schiffmann, MD
Lead Sponsor: Baylor Research Institute